Participated · Series B · Nov 2025

AAVantgarde Bio is advancing best-in-class AAV gene therapies aimed at treating severe inherited retinal diseases (IRDs) that currently have no approved therapies. Its lead candidate, AAVB-039, is being evaluated in the CELESTE study to address Stargardt disease caused by ABCA4 mutations, alongside the >100-patient STELLA natural history study. A second program, AAVB-081, is in a Phase 1/2 LUCE trial for retinitis pigmentosa secondary to Usher syndrome type 1B arising from MYO7A mutations. Led by CEO Dr. Natalia Misciattelli, the company plans to use newly secured capital to achieve clinical proof-of-concept for both programs. The pipeline positions AAVantgarde to enter mid-stage development in two large, unmet IRD markets. Financially, the company has just closed a substantial $141 million Series B round to fund these milestones, underscoring strong investor confidence in its platform. No revenue or patient adoption metrics have yet been disclosed, consistent with its clinical-stage status.

Participated · Debt Financing · Mar 2025

Crusoe Energy Systems develops and operates vertically integrated, energy-sourced data centers optimized for artificial-intelligence computing. Its flagship offering, Crusoe Cloud, provides high-performance GPU resources to customers such as Cursor, Decart, Fireworks, Odyssey and Together AI. The company combines rapid energy sourcing, proprietary data-center design, and a managed AI cloud platform to deliver lower-cost and lower-emission compute. To expand service breadth, Crusoe recently acquired Atero, a GPU management and memory-optimization firm, accelerating its managed AI services roadmap. Geographic expansion is underway: the firm is adding capacity in Norway and Iceland and has opened offices in Dublin, Sunnyvale, and Tel Aviv. Major build-outs include a 1.2-gigawatt data-center campus in Abilene, Texas, and a newly announced 1.8-gigawatt campus in Wyoming, with additional multi-gigawatt sites planned across the U.S. Following its latest financing, the company’s valuation is expected to exceed $10 billion, underscoring strong investor confidence in its growth trajectory.